401 related articles for article (PubMed ID: 35592330)
1. Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited].
Jawalagatti V; Kirthika P; Lee JH
Front Immunol; 2022; 13():884862. PubMed ID: 35592330
[TBL] [Abstract][Full Text] [Related]
2. Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2.
Jawalagatti V; Kirthika P; Hewawaduge C; Yang MS; Park JY; Oh B; Lee JH
Mol Ther; 2022 May; 30(5):1926-1940. PubMed ID: 35123065
[TBL] [Abstract][Full Text] [Related]
3. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
5. A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine.
Jawalagatti V; Kirthika P; Hewawaduge C; Park JY; Yang MS; Oh B; So MY; Kim B; Lee JH
Front Immunol; 2022; 13():811802. PubMed ID: 35250985
[TBL] [Abstract][Full Text] [Related]
6. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
8. mRNA vaccines against infectious diseases and future direction.
Aleem MT; Munir F; Shakoor A; Gao F
Int Immunopharmacol; 2024 Jun; 135():112320. PubMed ID: 38788451
[TBL] [Abstract][Full Text] [Related]
9. Advances of Reverse Vaccinology for mRNA Vaccine Design against SARS-CoV-2: A Review of Methods and Tools.
da Silva MK; Campos DMO; Akash S; Akter S; Yee LC; Fulco UL; Oliveira JIN
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896907
[TBL] [Abstract][Full Text] [Related]
10. mRNA vaccines for infectious diseases: principles, delivery and clinical translation.
Chaudhary N; Weissman D; Whitehead KA
Nat Rev Drug Discov; 2021 Nov; 20(11):817-838. PubMed ID: 34433919
[TBL] [Abstract][Full Text] [Related]
11. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
[TBL] [Abstract][Full Text] [Related]
12. The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology.
Ye Z; Harmon J; Ni W; Li Y; Wich D; Xu Q
ACS Nano; 2023 Aug; 17(16):15231-15253. PubMed ID: 37535899
[TBL] [Abstract][Full Text] [Related]
13. mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern.
Wang H; Chen Z; Wang Z; Li J; Yan Z; Yuan J; Zhu A; Chen L; Liu Y; Hu C; Zhu A; Li G; Li Y; Deng J; Ma L; Sui X; Miao W; Li J; Zheng X; Piao J; Yao Y; Rao J; Shan C; Yuan Z; Zhao J; Zhu T
Emerg Microbes Infect; 2022 Dec; 11(1):1550-1553. PubMed ID: 35604772
[TBL] [Abstract][Full Text] [Related]
14. Trans-Amplifying RNA Vaccines Against Infectious Diseases: A Comparison with Non-Replicating and Self-Amplifying RNA.
Zimmermann L; Erbar S
Methods Mol Biol; 2024; 2786():135-144. PubMed ID: 38814392
[TBL] [Abstract][Full Text] [Related]
15. Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases.
Vadovics M; Muramatsu H; Sárközy A; Pardi N
Methods Mol Biol; 2024; 2786():167-181. PubMed ID: 38814394
[TBL] [Abstract][Full Text] [Related]
16. Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components.
Busà R; Sorrentino MC; Russelli G; Amico G; Miceli V; Miele M; Di Bella M; Timoneri F; Gallo A; Zito G; Di Carlo D; Conaldi PG; Bulati M
Front Immunol; 2022; 13():856657. PubMed ID: 35401503
[TBL] [Abstract][Full Text] [Related]
17. Time and cost of administering COVID-19 mRNA vaccines in the United States.
Yarnoff B; Bodhaine S; Cohen E; Buck PO
Hum Vaccin Immunother; 2021 Nov; 17(11):3871-3875. PubMed ID: 34613860
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 mRNA vaccines: Platforms and current developments.
Szabó GT; Mahiny AJ; Vlatkovic I
Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
[TBL] [Abstract][Full Text] [Related]
19. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.
Milane L; Amiji M
Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669
[TBL] [Abstract][Full Text] [Related]
20. Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination.
Mades A; Chellamathu P; Kojima N; Lopez L; MacMullan MA; Denny N; Angel AN; Santacruz M; Casian JG; Brobeck M; Nirema N; Klausner JD; Turner F; Slepnev VI; Ibrayeva A
Sci Rep; 2021 Dec; 11(1):24448. PubMed ID: 34961780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
